BridgeBio Pharma, Inc. - 8-K Filing
BridgeBio Pharma entered into an at-the-market equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC on May 7, 2026, allowing the company to sell up to $500 million in common stock through these sales agents. The same day, it terminated its previous equity distribution agreement dated May 4, 2023. (Items: 1.01 Entry Into a Material Definitive Agreement, 1.02 Termination of a Material Definitive Agreement On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldma, 9.01 Financial Statements and Exhibits)
Tickers: $BBIO